Initial Experience with Vincristine, Adriam‐cin and Cisdichlorodiammine Platinum Combination Chemotherap‐ of Advanced Ovarian Carcinoma | Zendy

Sen Dilip K. | Zendy; Zaleha Siti | Zendy; Sivanesaratnam V. | Zendy; Adlan Ahmad | Zendy; Meng Looi Lai | Zendy

Premium

Initial Experience with Vincristine, Adriam‐cin and Cisdichlorodiammine Platinum Combination Chemotherap‐ of Advanced Ovarian Carcinoma

Author(s) -

Sen Dilip K.,

Zaleha Siti,

Sivanesaratnam V.,

Adlan Ahmad,

Meng Looi Lai

Publication year - 1985

Publication title -

asia‐oceania journal of obstetrics and gynaecology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.597

H-Index - 50

eISSN - 1447-0756

pISSN - 0389-2328

DOI - 10.1111/j.1447-0756.1985.tb00752.x

Subject(s) - nausea , vomiting , vincristine , medicine , ovarian carcinoma , stage (stratigraphy) , complete response , gastroenterology , carcinoma , oncology , ovarian cancer , chemotherapy , cancer , cyclophosphamide , biology , paleontology

A combination of Cis‐dichlorodiammine platinum, Adriam‐cin and Vincristine was used on two groups of patients with advanced ovarian carcinoma of epithelial origin (stage III and IV). In the first group of thirteen patients resistant to previous chemotherap‐, the overall response rate was 46.2% (six cases). 15.4% (two cases) showed complete response. In the second group of four patients who had no previous chemotherap‐, three cases showed partial response, and one case showed no response. Toxicit‐ consisted of nausea and vomiting, leukopaenia of less than 1000/ml in 4 cases and inappropriate ADH secretion in 2.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research